<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<pubmed-document>
<record>
<header>
<identifier>15953948</identifier>
<setSpec>0034-9887</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:author>Rojas S, Pamela</dc:author>
<dc:author>Lafourcade R, Mónica</dc:author>
<dc:author>Inostroza S, Jaime</dc:author>
<dc:author>Pinto C, María E</dc:author>
<dc:author>Giglio M, María S</dc:author>
<dc:author>Fernández V, Alejandra</dc:author>
<dc:author>Joyas M, Alejandro</dc:author>
<dc:author>García C, Patricia</dc:author>
<dc:author>Alcaide L, Berta</dc:author>
<dc:author>Cruz P, Carolina</dc:author>
<dc:author>Aguilera A, Liliana</dc:author>
<dc:author>Camponovo C, Rossanna</dc:author>
<dc:author>Ulloa F, María T</dc:author>
<dc:author>Porte T, Lorena</dc:author>
<dc:author>González A, Patricia</dc:author>
<dc:author>Prado J, Valeria</dc:author>
<dc:description xml:lang="en">BACKGROUND Telithromycin is a new ketolide antimicrobial, that can be useful for the treatment of respiratory infections. AIM To compare in vitro activity of telithromycin against respiratory pathogens, isolated in outpatient clinics. MATERIAL AND METHODS Two hundred eighty strains isolated from patients with respiratory infections, were studied. The strains studied were S pneumoniae, penicillin sensitive (SPNS:57); intermediate (SPNI:35), resistant (SPNR:25); S pyogenes (SP:57); H influenzae (HIN 51); M catarrhalis (MC:25) and S aureus meticillin sensitive (SAUS:30). Minimal inhibitory concentration (MIC) by broth microdilution was studied for telitrhomycin and levofloxacin in all strains. Other antimicrobials studied, but not in all strains were erythromycin, clindamycin, trimetoprim sulphamethoxazole, oxacillin, amoxicillin-clavulanic acid and cefuroxime. RESULTS All strains were sensible to telithromycin at a concentration -4 microg/ml. MIC 90 and its range for SPNS was 0.03 microg/ml (-0.004-0.12), for SPNI was 0.03 microg/ml (-0.004-025), for SPNR was 0.06 microg/ml (-0.004-0.25), for HIN was 2 microg/ml (0.12-4), for SP was 0.5 microg/ml (-0.004-2), for MC was 0.5 microg/ml (0.06-2) and for SAU was 0.25 microg/ml (0.06-0.25). CONCLUSIONS All studied pathogens were sensible to telithromycin in vitro. This antimicrobial is an alternative for the treatment of community acquired respiratory infections.</dc:description>
<dc:type>Journal Article</dc:type>
<dc:language>es</dc:language>
<dc:date>2005 Apr </dc:date>
<dc:title xml:lang="es">Estudio de la actividad comparativa in vitro de telitromicina en patógenos respiratorios adquiridos en la comunidad en 13 centros clínicos chilenos.</dc:title>
<dc:title xml:lang="en">[In vitro activity of telithromycin against community acquired respiratory pathogens].</dc:title>
<dc:publisher>Revista medica de Chile</dc:publisher>
</metadata>
</record>
</pubmed-document>
